Group 1 - Zai Lab Limited's shares increased by 14.7% to close at $33.18, with a significant trading volume compared to normal sessions, and a total gain of 42.3% over the past four weeks [1][2] - The stock price surge followed the announcement of a 74% objective response rate for ZL-1310 in a global phase Ia/Ib study for recurrent extensive-stage small cell lung cancer (SCLC), indicating strong potential for the investigational candidate [2] - Zai Lab plans to further evaluate ZL-1310 both as a single agent and in combination therapies for extensive-stage SCLC, following positive early-stage study results showing that the candidate was generally safe and well-tolerated [2] Group 2 - The company is expected to report a quarterly loss of $0.74 per share, reflecting a year-over-year decrease of 4.2%, while revenues are projected to be $103.54 million, representing a 49.6% increase from the previous year [2] - The consensus EPS estimate for Zai Lab has been revised 3.7% lower over the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not correlate with price appreciation [3] - Zai Lab is part of the Zacks Medical - Biomedical and Genetics industry, where another company, Adma Biologics, has also been noted with a Zacks Rank of 3 (Hold) [3][4]

Group 1 - Zai Lab Limited's shares increased by 11.1% to $22.60 in the last trading session, with a higher-than-average trading volume, compared to an 8.4% gain over the past four weeks [1] - The stock price surge is attributed to positive investor expectations regarding the performance of its marketed drugs: Zejula, Vyvgart, and Nuzyra, along with a strong pipeline of investigational drugs [1] - The company is projected to report a quarterly loss of $0.72 per share, reflecting a year-over-year change of -1.4%, while revenues are expected to reach $105.19 million, a 51.9% increase from the previous year [1] Group 2 - The consensus EPS estimate for Zai Lab has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [2] - Zai Lab currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [2] - Zai Lab is part of the Zacks Medical - Biomedical and Genetics industry, which includes TELA Bio, another stock in the same sector that closed 6.5% higher at $2.62 [2]

Group 1 - Zai Lab Limited (NASDAQ: ZLAB) develops therapies across various medical conditions including oncology, autoimmune, infectious, and neurological diseases [1] - The company has collaborated with leading firms to create approved products such as VYVGART, AUGTYRO, and XACDURO, retaining commercialization rights for China [1] - Recent policy reforms in China have supported Zai Lab's efforts, facilitating its operations and market presence [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ____________________ FORM 10-Q ____________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-38205 ____________________ ZAI LAB LIMITED (Exact Name of Registrant as Specif ...

Exhibit 99.1 Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates – Net product revenue of $100.1 million for the second quarter of 2024, representing 45% y-o-y growth; 47% y-o-y growth at constant exchange rate (CER) – VYVGART (efgartigimod alfa injection) sales of $23.2 million for the second quarter of 2024; raising full-year VYVGART revenue guidance to exceed $80.0 million ® – Expansion of Zai Lab's global oncology pipeline with a next generation ROR1 antibody-drug conjug ...

It’s not often that a genuine hidden-gem candidate appears in the market. But that label might apply to Chinese biotechnology firm Zai Lab (NASDAQ:ZLAB). Developing and commercializing a range of therapeutics, the company offers solutions for autoimmune disorders, infectious diseases and neurologic conditions. Arguably the most compelling business unit undergirding ZLAB stock, though, is oncology.According to its public profile, Zai Lab features a cancer therapy called Optune. This innovation uses electric ...

Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Investor Relations Samantha Du - Founder, Chairperson & Chief Executive Officer Josh Smiley - President & Chief Operating Officer Rafael Amado - President & Head-Global Oncology Research & Development Harald Reinhart - President & Head-Global Development, Neuroscience, Autoimmune & Infectious Diseases Yajing Chen - Chief Financial Officer Jonathan Wang - Chief B ...

Revenue and Sales Performance - Net product revenue for Q1 2024 was $87.1 million, a 39% increase from $62.8 million in Q1 2023, primarily driven by increased sales volume and the launch of VYVGART[89]. - Total product revenue for the first quarter of 2024 was $87.1 million, representing a 39% increase from $62.8 million in the same period of 2023[109]. - ZEJULA sales increased by 7% to $45.5 million, while QINLOCK saw a significant increase of 367% to $6.1 million[109]. - VYVGART was commercially launched in September 2023 and included in the NRDL in Q1 2024, contributing to revenue growth[106]. - QINLOCK and NUZYRA saw increased sales due to their inclusion in the NRDL, with QINLOCK added in Q1 2023 and NUZYRA's oral formulation added in Q1 2024[106]. - ZEJULA remained the leading PARP inhibitor in hospital sales for ovarian cancer in mainland China, with continued support from NRDL listings[106]. Expenses and Losses - The cost of sales increased by 58% to $33.6 million in Q1 2024 from $21.3 million in Q1 2023, reflecting higher product sales volume[103]. - Research and development expenses rose by 13% to $54.6 million in Q1 2024 compared to $48.5 million in Q1 2023, indicating continued investment in product development[103]. - Selling, general, and administrative expenses increased by 11% to $69.2 million in Q1 2024 from $62.5 million in Q1 2023, supporting commercial operations[103]. - The net loss for Q1 2024 was $53.5 million, a 9% increase from a net loss of $49.1 million in Q1 2023[103]. - The company’s net loss increased by $4.3 million in Q1 2024, contributing to the rise in cash used in operating activities[140]. Cash Flow and Financial Position - As of March 31, 2024, the company had cash and cash equivalents of $750.8 million, expected to meet cash requirements for at least the next 12 months[136]. - The company reported a net decrease in cash, cash equivalents, and restricted cash of $39.4 million in Q1 2024, an improvement from a decrease of $128.4 million in Q1 2023[139]. - Net cash used in operating activities increased by $20.8 million to $90.1 million in Q1 2024, primarily due to a $24.7 million increase in net changes in operating assets and liabilities[140]. - Net cash provided by investing activities was $3.3 million in Q1 2024, a significant shift from net cash used of $54.0 million in Q1 2023, mainly due to a $100.0 million decrease in purchases of short-term investments[141]. - Net cash provided by financing activities was $47.5 million in Q1 2024, compared to net cash used of $3.9 million in Q1 2023, driven by $48.2 million in proceeds from short-term debts[142]. - The company had cash and cash equivalents of $650.8 million as of March 31, 2024, down from $790.2 million as of December 31, 2023[153]. Research and Development - Clinical program expenses within R&D increased by 50% to $18.8 million, driven by newly initiated studies[114]. - Research and development expenses rose by 13% to $54.6 million, primarily due to a $7.5 million increase in CROs/CMOs/Investigators expenses[112]. Debt and Obligations - As of March 31, 2024, the company may be required to pay up to $303.5 million in development and regulatory milestone payments for current clinical programs[101]. - The company entered into debt arrangements allowing subsidiaries to borrow up to approximately $164.5 million to support working capital needs[137]. Foreign Currency and Interest - Foreign currency losses amounted to $2.1 million in the first quarter of 2024, contrasting with a gain of $8.9 million in the same period of 2023[119]. - Interest income decreased by $0.6 million to $9.7 million due to reduced cash and cash equivalents[117]. Customer Concentration - As of March 31, 2024, accounts receivable from the two largest customers accounted for approximately 21% of total accounts receivable[154]. Accounting Standards - The company has not adopted any new accounting standards since December 31, 2023[144]. Foreign Exchange Risk - The company has not used derivative financial instruments to hedge foreign exchange risk, as it does not currently have significant direct exposure[147].

Exhibit 99.1 Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates – Net product revenue of $87.1 million for the first quarter of 2024, representing 39% y-o-y growth; 43% y-o-y growth at constant exchange rate (CER) ® – VYVGART (efgartigimod alfa injection) sales of $13.2 million for the first quarter of 2024, driven by increased patient access; an estimated 2,700 new patients were treated with VYVGART in the first quarter of 2024 – Regulatory reviews ongoing for sulbactam-dur ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will present findings from preclinical studies highlighting the therapeutic potential of ZL-1310, the company’s global next-generation antibody-drug conjugate (ADC) program. The preclinical profile of ZL-1310 will be the focus of a poster presentation at the European Lung Cancer Congress 2024 (ELCC 2024), scheduled for March 20-23, 2024 in Prague, Czech Republic. ZL-1310 is a novel and promisi ...